Traders sold shares of Stryker Corp. (NYSE:SYK) on strength during trading on Tuesday after an insider sold shares in the company. $48.64 million flowed into the stock on the tick-up and $104.91 million flowed out of the stock on the tick-down, for a money net flow of $56.27 million out of the stock. Of all stocks tracked, Stryker Corp. had the 0th highest net out-flow for the day. Stryker Corp. traded up $3.06 for the day and closed at $109.74Specifically, Director Ronda E. Stryker sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $113.07, for a total transaction of $1,356,840.00. Following the transaction, the director now directly owns 193,142 shares in the company, valued at approximately $21,838,565.94. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $115.67, for a total transaction of $694,020.00. Following the transaction, the director now owns 193,142 shares in the company, valued at $22,340,735.14. The disclosure for this sale can be found here. Corporate insiders own 7.80% of the company’s stock.

SYK has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Stryker Corp. from a “sell” rating to a “hold” rating and set a $129.00 target price on the stock in a research report on Monday, October 31st. Canaccord Genuity restated a “buy” rating and set a $130.00 target price on shares of Stryker Corp. in a research report on Sunday, July 24th. Credit Suisse Group AG restated an “outperform” rating and set a $124.00 target price (up from $110.00) on shares of Stryker Corp. in a research report on Tuesday, July 19th. BMO Capital Markets upgraded shares of Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 target price on the stock in a research report on Tuesday, November 1st. They noted that the move was a valuation call. Finally, SunTrust Banks Inc. initiated coverage on shares of Stryker Corp. in a research report on Thursday, October 13th. They set a “buy” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $122.38.

The firm’s 50-day moving average is $115.24 and its 200-day moving average is $114.92. The stock has a market capitalization of $41.09 billion, a price-to-earnings ratio of 24.97 and a beta of 0.86.

Stryker Corp. (NYSE:SYK) last issued its earnings results on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the firm earned $1.25 earnings per share. Stryker Corp.’s revenue for the quarter was up 17.1% on a year-over-year basis. Equities analysts anticipate that Stryker Corp. will post $5.78 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Cohen Lawrence B raised its position in shares of Stryker Corp. by 0.5% in the second quarter. Cohen Lawrence B now owns 59,768 shares of the medical technology company’s stock worth $7,162,000 after buying an additional 320 shares during the last quarter. CenturyLink Investment Management Co raised its position in shares of Stryker Corp. by 5.9% in the second quarter. CenturyLink Investment Management Co now owns 5,237 shares of the medical technology company’s stock worth $628,000 after buying an additional 292 shares during the last quarter. Moreno Evelyn V raised its position in shares of Stryker Corp. by 0.4% in the second quarter. Moreno Evelyn V now owns 62,035 shares of the medical technology company’s stock worth $7,434,000 after buying an additional 225 shares during the last quarter. Rosenbaum Jay D. raised its position in shares of Stryker Corp. by 3.2% in the second quarter. Rosenbaum Jay D. now owns 13,820 shares of the medical technology company’s stock worth $1,656,000 after buying an additional 428 shares during the last quarter. Finally, Raymond James Trust N.A. raised its position in shares of Stryker Corp. by 5.4% in the second quarter. Raymond James Trust N.A. now owns 17,919 shares of the medical technology company’s stock worth $2,147,000 after buying an additional 919 shares during the last quarter. 74.46% of the stock is currently owned by institutional investors.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.